KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $1.5 million.

  • Nektar Therapeutics' Capital Expenditures fell 82.88% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $612,000, marking a year-over-year decrease of 50.88%. This contributed to the annual value of $1.5 million for FY2024, which is 69.71% up from last year.
  • Per Nektar Therapeutics' latest filing, its Capital Expenditures stood at $1.5 million for FY2024, which was up 69.71% from $865,000 recorded in FY2023.
  • Nektar Therapeutics' Capital Expenditures' 5-year high stood at $15.0 million during FY2021, with a 5-year trough of $865,000 in FY2023.
  • Moreover, its 3-year median value for Capital Expenditures was $1.5 million (2024), whereas its average is $2.7 million.
  • Per our database at Business Quant, Nektar Therapeutics' Capital Expenditures skyrocketed by 106.52% in 2021 and then plummeted by 84.76% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Capital Expenditures (Yearly) stood at $7.3 million in 2020, then skyrocketed by 106.52% to $15.0 million in 2021, then tumbled by 62.13% to $5.7 million in 2022, then plummeted by 84.76% to $865,000 in 2023, then spiked by 69.71% to $1.5 million in 2024.